130 related articles for article (PubMed ID: 37342284)
1. Identification of inhibitors against SARS-CoV-2 variants of concern using virtual screening and metadynamics-based enhanced sampling.
Mandal N; Rath SL
Chem Phys; 2023 Sep; 573():111995. PubMed ID: 37342284
[TBL] [Abstract][Full Text] [Related]
2. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
Ebrahimi M; Karami L; Alijanianzadeh M
Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
[TBL] [Abstract][Full Text] [Related]
3. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
5. Virtual Screening of Repurposed Drugs as Potential Spike Protein Inhibitors of Different SARS-CoV-2 Variants: Molecular Docking Study.
Eweas AF; Osman HH; Naguib IA; Abourehab MAS; Abdel-Moneim AS
Curr Issues Mol Biol; 2022 Jul; 44(7):3018-3029. PubMed ID: 35877432
[TBL] [Abstract][Full Text] [Related]
6. Identification of potential inhibitors of omicron variant of SARS-Cov-2 RBD based virtual screening, MD simulation, and DFT.
Lü X; Feng C; Lü R; Wei X; Fan S; Yan M; Zhu X; Zhang Z; Yang Z
Front Chem; 2022; 10():1063374. PubMed ID: 36569957
[TBL] [Abstract][Full Text] [Related]
7. A Novel Real-Time RT-PCR-Based Methodology for the Preliminary Typing of SARS-CoV-2 Variants, Employing Non-Extendable LNA Oligonucleotides and Three Signature Mutations at the Spike Protein Receptor-Binding Domain.
Chaintoutis SC; Chassalevris T; Balaska S; Mouchtaropoulou E; Tsiolas G; Vlatakis I; Tychala A; Koutsioulis D; Argiriou A; Skoura L; Dovas CI
Life (Basel); 2021 Sep; 11(10):. PubMed ID: 34685386
[TBL] [Abstract][Full Text] [Related]
8. Metadynamics-based enhanced sampling protocol for virtual screening: case study for 3CLpro protein for SARS-CoV-2.
Namsani S; Pramanik D; Khan MA; Roy S; Singh JK
J Biomol Struct Dyn; 2022 Sep; 40(15):7002-7017. PubMed ID: 33663346
[TBL] [Abstract][Full Text] [Related]
9. Corilagin and 1,3,6-Tri-
Binette V; Côté S; Haddad M; Nguyen PT; Bélanger S; Bourgault S; Ramassamy C; Gaudreault R; Mousseau N
Phys Chem Chem Phys; 2021 Jul; 23(27):14873-14888. PubMed ID: 34223589
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based Design of Novel Peptidomimetics Targeting the SARS-CoV-2 Spike Protein.
Alagumuthu M; Rajpoot S; Baig MS
Cell Mol Bioeng; 2021 Apr; 14(2):177-185. PubMed ID: 33072222
[TBL] [Abstract][Full Text] [Related]
11. SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1.
Law JLM; Logan M; Joyce MA; Landi A; Hockman D; Crawford K; Johnson J; LaChance G; Saffran HA; Shields J; Hobart E; Brassard R; Arutyunova E; Pabbaraju K; Croxen M; Tipples G; Lemieux MJ; Tyrrell DL; Houghton M
Vaccine; 2021 Sep; 39(40):5769-5779. PubMed ID: 34481699
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
13. Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell-entry process, and cytokine storm in COVID-19.
Kar P; Saleh-E-In MM; Jaishee N; Anandraj A; Kormuth E; Vellingiri B; Angione C; Rahman PKSM; Pillay S; Sen A; Naidoo D; Roy A; Choi YE
J Cell Biochem; 2022 May; 123(5):964-986. PubMed ID: 35342986
[TBL] [Abstract][Full Text] [Related]
14. Recognition through GRP78 is enhanced in the UK, South African, and Brazilian variants of SARS-CoV-2; An in silico perspective.
Ibrahim IM; Elfiky AA; Elgohary AM
Biochem Biophys Res Commun; 2021 Jul; 562():89-93. PubMed ID: 34049205
[TBL] [Abstract][Full Text] [Related]
15. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
16. In Silico Identification of New Anti-SARS-CoV-2 Main Protease (M
Onyango H; Odhiambo P; Angwenyi D; Okoth P
J Trop Med; 2022; 2022():3697498. PubMed ID: 36263438
[TBL] [Abstract][Full Text] [Related]
17. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.
Westendorf K; Žentelis S; Wang L; Foster D; Vaillancourt P; Wiggin M; Lovett E; van der Lee R; Hendle J; Pustilnik A; Sauder JM; Kraft L; Hwang Y; Siegel RW; Chen J; Heinz BA; Higgs RE; Kallewaard NL; Jepson K; Goya R; Smith MA; Collins DW; Pellacani D; Xiang P; de Puyraimond V; Ricicova M; Devorkin L; Pritchard C; O'Neill A; Dalal K; Panwar P; Dhupar H; Garces FA; Cohen CA; Dye JM; Huie KE; Badger CV; Kobasa D; Audet J; Freitas JJ; Hassanali S; Hughes I; Munoz L; Palma HC; Ramamurthy B; Cross RW; Geisbert TW; Menacherry V; Lokugamage K; Borisevich V; Lanz I; Anderson L; Sipahimalani P; Corbett KS; Yang ES; Zhang Y; Shi W; Zhou T; Choe M; Misasi J; Kwong PD; Sullivan NJ; Graham BS; Fernandez TL; Hansen CL; Falconer E; Mascola JR; Jones BE; Barnhart BC
bioRxiv; 2022 Mar; ():. PubMed ID: 33972947
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
19. Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness.
Tulimilli SV; Dallavalasa S; Basavaraju CG; Kumar Rao V; Chikkahonnaiah P; Madhunapantula SV; Veeranna RP
Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298616
[TBL] [Abstract][Full Text] [Related]
20. Identification of potent compounds against SARs-CoV-2: An in-silico based drug searching against Mpro.
Hassam M; Bashir MA; Shafi S; Zahra NU; Khan K; Jalal K; Siddiqui H; Uddin R
Comput Biol Med; 2022 Dec; 151(Pt A):106284. PubMed ID: 36370580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
